Morten Harket, a-ha's Lead Singer, Reveals Parkinson's Diagnosis
Harket, 65, revealed his illness in an interview with Jan Omdahl, a-ha's biographer, on the band's website. Harket did not say when he received the diagnosis.
'I've got no problem accepting the diagnosis,' he said. 'With time I've taken to heart my 94-year-old father's attitude to the way the organism gradually surrenders: 'I use whatever works.''
His announcement comes days after the 40th anniversary of the release of a-ha's first album, 'Hunting High and Low,' on June 1, 1985. The first single from the album, 'Take on Me,' became a global hit that year, reaching No. 1 on the Billboard Hot 100 in the United States on the basis of the song's infectious synthesizer hook and innovative video that mixed animation with live action.
In the interview, Harket said he took medicine to manage his symptoms. Last June, he traveled to the United States, where surgeons at the Mayo Clinic implanted, inside the left side of his brain, electrodes that receive electrical impulses from a small pacemaker-like device in his upper chest. He underwent the same procedure in December for the right side of his brain.
The treatment, known as deep brain simulation, is an established treatment for Parkinson's. Omdahl writes that the treatment has helped keep Harket's symptoms in check.
Still, problems with his voice 'are one of many grounds for uncertainty about my creative future,' he said. The dopamine supplements that he takes affect his voice, but his underlying symptoms become more pronounced if he doesn't take them, he said.
Parkinson's is a progressive and incurable disease that affects the central nervous system and causes tremors, muscle stiffness, impaired balance and other symptoms. More than 10 million people worldwide are estimated to be living with Parkinson's, according to the Parkinson's Foundation.
Harket, who has released six solo albums, said he has worked on songs in recent years.
A-ha formed in Oslo in 1982. Harket and his two bandmates, Paul Waaktaar-Savoy and Magne Furuholmen, spent their early days playing in London before they eventually landed a contract with Warner Bros.
Though a-ha is largely known as a one-hit wonder in the United States for 'Take On Me,' its second single, 'The Sun Always Shines on TV,' cracked the Top 20 of the Billboard Hot 100 singles chart in 1985. The band went on to sell millions of copies of its albums worldwide, and has performed before audiences in 38 countries. Its most recent studio album, 'True North,' was issued in 2022.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
9 hours ago
- Fox News
Stanford scientists 'totally surprised' by potential Parkinson's treatment discovery
A recent study from Stanford Medicine that "totally surprised" researchers highlighted what could be a promising approach to slowing Parkinson's disease progression. The research, published in the journal Science Signaling, took a closer look at enzymes — proteins in the body that speed up chemical reactions and are essential for digestion, liver function and other key functions, according to Cleveland Clinic — and their role in Parkinson's. The team found that targeting a certain enzyme helped to restore neuron and cell communication in mice. Lead author Suzanne Pfeffer, PhD, the Emma Pfeiffer Merner Professor in Medical Sciences and a professor of biochemistry at Stanford, told Fox News Digital that the team was "totally surprised that we saw as much improvement as we did." In about 25% of Parkinson's cases, the culprit is some form of genetic mutation. One of the most common mutations creates an overactive enzyme called LRRK2, according to a Stanford press release. When there is too much LRRK2 activity, it changes the structure of the brain cells, disrupting important communication between neurons and cells. This system is crucial to movement, motivation and decision-making, according to the researchers. The goal of the study was to determine whether a specific molecule — the MLi-2 LRRK2 kinase inhibitor — could reverse the effect of overactive enzymes. Using mice that had the genetic mutation that causes overactive LRRK2 and also had symptoms consistent with early Parkinson's disease, the scientists tried feeding them the inhibitor for two weeks. There were initially no changes detected in brain structure, signaling or function of the dopamine neurons. However, after three months of eating the inhibitor, mice affected by the overactive enzyme appeared to have restored their neurons to the point where they were virtually the same as those without the genetic mutation, the study found. "Findings from this study suggest that inhibiting the LRRK2 enzyme could stabilize the progression of symptoms if patients can be identified early enough," Pfeffer said in the press release. The study did have some limitations, the researchers acknowledged. "This was in mice, not people, but our current results indicate that similar pathways are important in humans," Pfeffer told Fox News Digital. While the study focused on a specific genetic form of the disease, overactive LRRK2 is also present in other cases, meaning this treatment could help multiple types of Parkinson's patients and possibly those with other neurodegenerative diseases, the reseachers claimed. Looking ahead, the team plans to investigate whether other forms of Parkinson's could benefit. Parkinson's — a disease that involves the slow death of dopamine-producing neurons, leading to symptoms like tremors and stiffness — affects nearly one million Americans, according to the Parkinson's Foundation, which has offices in New York and Miami. Experts agree that early intervention is key, as Parkinson's symptoms often appear years after the disease begins. "These findings suggest that it might be possible to improve, not just stabilize, the condition of patients with Parkinson's disease." Identifying and treating at-risk individuals sooner could potentially halt or reverse neuron loss. "These findings suggest that it might be possible to improve, not just stabilize, the condition of patients with Parkinson's disease," Pfeffer said. For more Health articles, visit The researcher told Fox News Digital that it's important to encourage patients to undergo genetic testing to learn more about their suitability for clinical trials and future treatments. The study was funded by The Michael J. Fox Foundation for Parkinson's Research, the Aligning Science Across Parkinson's initiative and the United Kingdom Medical Research Council.
USA Today
10 hours ago
- USA Today
Is Chick-fil-A healthy? Fast-food chain named one of the least nutritious in America
The CDC considers obesity a serious, common and costly chronic disease with more than two in five U.S. adults having it. The dominance of unhealthy foods in America is a big offender. WorldAtlas recently ranked the 10 worst fast-food chains, looking at their nutrition data, menu gimmicks and marketing tactics at major chains. One beloved favorite rounds out the list of the 10 that "routinely serve meals that can eclipse daily calorie limits in a single sitting while encouraging visits through bargain pricing and around-the-clock service." Is Chick-fil-A healthy? Here's what WorldAtlas said about the chain: "Chick-fil-A masks calorie-dense fried-chicken fare behind a wholesome image. An 'original chicken sandwich' with medium waffle fries delivers ~ 750 mg sodium, about one-third of a day's limit, and 800 calories, while sugary lemonade and milkshakes push totals sky-high. The chain dialed back its 'No Antibiotics Ever' pledge in 2024, though its 2026 cage-free-egg goal remains. With 3,200-plus U.S. outlets and drive-throughs generating 60% of sales, Chick-fil-A encourages frequent, on-the-go indulgence nationwide." Are Chick-fil-A salads healthy? Below is nutritional data for Chick-fil-A's salads. These figures will change depending on the protein topping: In case you missed it: Chick-fil-A's only all-you-can-eat location is in Oklahoma. Here's what you need to know How many Chick-fil-A locations are in America? Chick-fil-A currently has more than 3,000 restaurant locations in the U.S., according to its official website. This includes restaurants, drive-thru spots, airport kiosks, and more. Texas leads the country with 500 locations throughout the state. What is the most unhealthy fast food restaurant? Here's a look at the full list WorldAtlas provided: Miguel Legoas is a Deep South Connect Team Reporter for Gannett/USA Today. Find him on Instagram @miguelegoas and email at mlegoas@
Gizmodo
13 hours ago
- Gizmodo
This Cough Syrup Ingredient Might Actually Slow Dementia
Today's cough syrup could turn into tomorrow's treatment for Parkinson's disease. Recent research in the U.K. is the latest to suggest that a common ingredient in cough syrup, ambroxol, might be able to slow down the progression of Parkinson's. Scientists at St. Joseph's Health Care London conducted the year-long small study, which involved 55 patients with Parkinson's-related dementia. The drug was safely tolerated and may have stabilized people's symptoms, particularly people more genetically vulnerable to the neurodegenerative disease. Researchers elsewhere have already begun to test ambroxol for Parkinson's and related dementias in larger trials. 'These findings suggest Ambroxol may protect brain function, especially in those genetically at risk. It offers a promising new treatment avenue where few currently exist,' said study author Stephen Pasternak, a cognitive neuroscientist at Lawson Research Institute, the research arm of St. Joseph's Health Care London, in a statement from the university. The Surprising Connection Between Living Near Golf Courses and Parkinson's Disease Ambroxol is commonly used as an expectorant in cough syrup, helping thin out mucus so people with respiratory illnesses can clear phlegm from their airways and breathe easier. But recently, scientists have speculated that it can also target a key driver of Parkinson's, the accumulation of abnormal alpha-synuclein in the brain. Studies have found that ambroxol can raise people's levels of glucocerebrosidase (GCase), another protein that helps regulate the brain's waste clearance system. In people with Parkinson's, levels of GCase tend to decline as levels of abnormal alpha-synuclein rise. It's also known that people with certain genetic mutations affecting GCase function are at higher risk for Parkinson's. Scientists have hoped that ambroxol can indirectly lower people's alpha-synuclein by increasing GCase, reversing or at least slowing down the progression of Parkinson's. The researchers randomized people with Parkinson's-related dementia to either receive a placebo or a high dose of ambroxol (taken via pills daily) over a 12-month span. There were no severe symptoms linked to the drug's use, the researchers found, and common adverse effects were typically gastrointestinal. People on placebo also experienced worsening psychiatric symptoms of their Parkinson's and an increase in levels of GFAP (a blood marker of brain damage), whereas those on ambroxol appeared to stay about the same. 'This early trial offers hope and provides a strong foundation for larger studies,' Pasternak said. The team's results, published late last month in JAMA Neurology, were not a clear home run, however. There was overall no difference in cognition between the placebo and treatment groups, for instance. People with GCase-related genetic mutations taking the drug may have experienced improved cognition, though the sample sizes were too small to know for sure. Scientists Are Testing an Old Cough Medicine as a Parkinson's Disease Treatment That said, enough evidence has built up that other scientists are taking a chance on ambroxol. There are at least three clinical trials of the drug for Parkinson's and similar conditions linked to GCase underway right now. The largest of these trials is testing ambroxol in over 300 people with Parkinson's over a two-year span. It will take years for these studies to wrap up, but if successful, ambroxol could very well become the first treatment able to slow down the destruction caused by Parkinson's.
